NYSE:EVMN News | QuoteStream

quartr

EVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum

Chronic inflammation remains a major unmet need, with two novel programs—EVO756 and EVO301—advancing through Phase 2 trials targeting atopic dermatitis and migraine. Both candidates show strong efficacy and safety, supported by a robust financial position and experienced leadership.Original documen…

Quartr en_IN 7/8/2026, 05:19 am GMT+8

StocksUS

EVMN

tradingview

Evommune initiates Phase 2b trial of EVO756 for migraine, top-line data expected in 2027

Evommune initiated dosing in a global Phase 2b trial of EVO756 for migraine prophylaxis; top-line data expected in 2027.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Jul. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informati…

TradingView en_IN 30/7/2026, 08:03 pm GMT+8

StocksUS